Abstract
TROCAI is a phenotypic tropism test developed using the virological response to a short-term exposure to maraviroc monotherapy (Maraviroc Clinical Test [MCT]). It was found that with TROCAI, a cutoff of <0.5% of dual/mixed viruses was needed to predict R5 HIV tropism. Here, we have validated TROCAI, using this cutoff, in a new cohort of 42 patients, finding a very high concordance between TROCAI and MCT (98%), and a good concordance (71 to 87%) with other genotypic/phenotypic methods.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Cyclohexanes / pharmacology*
-
HIV / drug effects*
-
HIV / physiology
-
HIV Fusion Inhibitors / pharmacology*
-
Humans
-
Inhibitory Concentration 50
-
Maraviroc
-
Triazoles / pharmacology*
-
Viral Tropism / drug effects*
-
Viral Tropism / physiology
-
Virology / methods*
Substances
-
Cyclohexanes
-
HIV Fusion Inhibitors
-
Triazoles
-
Maraviroc
Grants and funding
This work was supported by Redes Telemáticas de Investigación Cooperativa en Salud (RETICS; 2006, Red de SIDA RD06/0006/0021, 2007–2010, and RD16/0025/0020) and Pfizer/ViiV Healthcare (grants WS843473 and WS2425049).